Management of HF Across the EF Spectrum

Published: 16 November 2021

  • Views:

    Views Icon 61
  • Likes:

    Heart Icon 0

Overview

Full programme

  • Views:

    Views Icon 61
  • Likes:

    Heart Icon 0

Overview

How do you define heart failure (HF)? Is ejection fraction (EF) even the best determinant of therapy choice anymore? Perhaps there is utility in considering other patient characteristics too?
 

Whatever your view, the definition of HF is fluid, with different EF cut-offs having been adopted across diferent trials, making it challenging for guideline committees to make clear recommendations for treatment choice – particularly in patients with an EF in the range of 40–60. For these patients, prescribers must make their own decisions based on their interpretation of trial data, married with their own clinical judgement. 
 

Catch up on-demand with this educational programme, in which we consider where management is heading across the spectrum of ejection fraction. Chaired by Dr Jeyamalar Rajadurai of Subang Jaya Medical Centre and with expert insight from Prof Akshay Desai of Brigham and Women’s Hospital, this meet the expert session will explore the pathophysiology across the EF spectrum of HF, how it manifests in both shared and distinct clinical features and then how to use current clinical trial data to treat effectively.
 

This programme is being endorsed by the National Heart Association of Malaysia 

This broadcast is being supported by an unrestricted educational grant by Novartis and endorsed by:

Key Learning Objectives

  • Recall the shared pathophysiology across the spectrum of heart failure with respect to patient characteristics, trial outcomes, and prognosis
  • Select evidence-based therapies likely to achieve benefit in patients with HFmrEF and HFpEF
  • Recall the outcomes of recent meta-analyses, registries and pooled analyses assessing the performance of established heart failure agents across patients with an ejection fraction >40%
  • Identify patient sub-groups with HFmrEF or HFpEF likely to gain benefit from established HFrEF medications

Target Audience

  • HF Cardiologists

Series overview

Part 1

Pathophysiology across the spectrum of EF

1 session

  • Pathophysiology across the spectrum of EF

    Watch now

Part 2

Applying emerging HFpEF data to practice?

1 session

  • Applying emerging HFpEF data to practice?

    Watch now

Part 3

Q&A

1 session

Faculty biographies